Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

Stanley S Schwartz1,2
Arie Katz3
1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA

Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic defects contributing to hyperglycemia may improve patient outcomes. For many patients, the combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be a good option because these agents have complementary mechanisms of action, neutral-to-positive effects on body weight, and a low risk of hypoglycemia. This review focuses on the combination of metformin with dapagliflozin, a member of the SGLT-2 inhibitor class of antidiabetes agents. In clinical trials, the combination of dapagliflozin with metformin produced significant and sustained reductions in glycated hemoglobin and body weight in a broad range of adult patients with T2D, including those initiating pharmacotherapy and those with more advanced disease. These reductions were accompanied by modest decreases in blood pressure. Dapagliflozin as add-on therapy to metformin was well tolerated and associated with low rates of hypoglycemia. Genital infections and, in some studies, urinary tract infections were more frequent with dapagliflozin than with placebo. Early combination therapy with dapagliflozin and metformin may be a safe and appropriate treatment option that enables patients with T2D to achieve individualized glycemic goals as either initial combination therapy in treatment-naïve patients or as dapagliflozin add-on in patients inadequately controlled with metformin therapy.

Keywords: combination therapy, dapagliflozin, metformin

Introduction
The prevalence of diabetes is rapidly increasing coincident with the obesity epidemic.1 In 2014, the global prevalence of diabetes was estimated at 387 million people, mostly with type 2 diabetes (T2D), and this is expected to rise to 592 million by 2035.2 In healthy individuals, numerous organs, hormones, and neurotransmitters work in concert via complex feedback mechanisms to tightly control plasma glucose concentrations.3 The pathophysiology of T2D involves dysfunction at multiple levels of this complex system1,4 (Figure 1), and β-cell dysfunction and insulin resistance are major contributors to the development and progression of T2D.3

The progressive nature of T2D, its complex pathophysiology, and the frequent presence of multiple comorbidities make management challenging. Although lifestyle changes (ie, diet and exercise) can improve glycemic control and cardiovascular (CV) risk factors in T2D,1 most patients do not adhere to such changes over the long term and
subsequently require pharmacotherapy to achieve glycemic goals. Furthermore, despite a wide range of available treatment options, only ~50% of patients with diabetes in the United States have glycated hemoglobin (A1c) <7%.9,10

Chronic uncontrolled hyperglycemia increases the risk of microvascular complications (nephropathy, retinopathy, and neuropathy), macrovascular complications (CV disease), and mortality. Data from the Diabetes Control and Complications Trial (DCCT) and its long-term follow-up study, Epidemiology of Diabetes Interventions and Complications (EDIC) in patients with type 1 diabetes, and from the UK Prospective Diabetes Study (UKPDS) in patients with T2D suggest that intensive glycemic control, particularly when achieved early in the disease course, can reduce the risk of microvascular and, to a lesser extent, macrovascular complications and mortality. In the Steno-2 trial, intensive glycemic control (targeted A1c <6.5%) and multifactorial intervention that targeted hypertension, dyslipidemia, microalbuminuria, and secondary prevention of CV disease with aspirin resulted in a lower risk of CV disease and microvascular complications compared with conventional treatment. A long-term follow-up of the Steno-2 trial (13.3 years) found a 20% reduction in all-cause mortality among patients receiving intensive therapy vs patients receiving conventional therapy, even though the between-group differences in glycemic control and CV risk factors had disappeared during the follow-up period. A similar “legacy effect” or “metabolic memory” was observed in the UKPDS and DCCT/EDIC trials, supporting the view that early glycemic intervention in patients with diabetes reduces complications over the long term.

Conflicting results were observed in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, the Veterans Affairs Diabetes Trial (VADT), and the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial, in which intensive glycemic control resulted in no significant reductions in CV outcomes in patients with T2D and established CV disease and/or multiple CV risk factors. In the ACCORD trial, intensive glycemic control (target A1c <6.0%) compared with standard therapy (target A1c 7.0%–7.9%) was associated with an increase in mortality. Subsequent analysis of the ACCORD data suggested that persistently high A1c on treatment was associated with an increased risk of mortality in the intensive treatment arm. Severe hypoglycemia was associated with an increased risk of death in both treatment arms. Although individuals in the intensive treatment arm had more episodes of hypoglycemia and severe hypoglycemia than those in the standard treatment arm, differences in the number and severity of hypoglycemic events did not appear to account for the increased mortality observed in the intensive treatment arm. However, it

Figure 1 Mechanisms involved in hyperglycemia in T2D and site of action of metformin and dapagliflozin.

Note: Through direct and indirect mechanisms, combination therapy with metformin and dapagliflozin may reduce hyperglycemia via effects on several of these pathways. Abbreviations: GI, gastrointestinal; GLP-1, glucagon-like peptide-1; T2D, type 2 diabetes.
should be noted that hypoglycemia was only assessed by patients reporting events post hoc, during routine visits. Moreover, blood glucose measurements were not available at the time of death for patients who died. Weight gain was higher in the intensive treatment arm, likely associated with the use of insulin and thiazolidinediones, and may have contributed to the increased mortality risk. In a recently published analysis of the ACCORD trial data, there was no significant association of insulin dose with CV mortality. Our view is that hypoglycemia and weight gain should be avoided in patients under our care.

Taken together, the results from the large interventional trials suggest that improved glycemic control early in the course of the disease with agents associated with low risk of hypoglycemia and weight gain, combined with treatment of CV risk factors, may be the best approach to comprehensive care for individuals with T2D.

Failure to initiate or intensify treatment to achieve glycemic goals (ie, treatment inertia) represents a major barrier to effective management of T2D. For example, in a retrospective cohort study of 81,573 patients with T2D, time to intensification of treatment in some patients was ≥7 years, resulting in prolonged duration of poor glycemic control. Evidence-based treatment guidelines recommend metformin as first-line pharmacotherapy for most patients, adding other classes of antidiabetes agents if glycemic goals are not achieved within 3 months. Early combination therapy with agents that target several of the underlying defects contributing to hyperglycemia, especially when A1C is ≥9%, may improve patient outcomes. The combination of metformin with a sodium–glucose cotransporter-2 (SGLT-2) inhibitor may be a good option for many patients, because these agents have complementary mechanisms of action, neutral-to-positive effects on body weight, and low risk of hypoglycemia. This review focuses on the combination of metformin with dapagliflozin, a member of the SGLT-2 inhibitor class of antidiabetes agents.

Mechanisms of action of dapagliflozin and metformin
The kidney plays an important role in glucose homeostasis. The kidney uses glucose for its energy needs and, in the fasting state, ~10% of total systemic glucose uptake is by the kidneys. In addition, it is the only organ capable of gluconeogenesis other than the liver, after an overnight fast, ~20% of total glucose production can be attributed to kidney gluconeogenesis. Most important, the major contribution of the kidneys to glucose homeostasis is the reabsorption of filtered glucose. In healthy individuals, virtually all of the glucose that is filtered by the glomerulus is reabsorbed. SGLT-2 is responsible for approximately 90% of the glucose reabsorption under normal conditions. In individuals with T2D, the capacity of the kidney to reabsorb glucose is increased, possibly a result of SGLT-2 upregulation in response to chronic hyperglycemia, leading to excessive glucose reabsorption and further exacerbation of the existing hyperglycemia.

Dapagliflozin is a highly selective SGLT-2 inhibitor that improves glycemic control independently of insulin secretion or action by reducing the reabsorption of filtered glucose and increasing glucose excretion in the urine. Dapagliflozin is associated with a reduction in body weight, secondary to increased glucose excretion and related caloric loss, and a reduction in blood pressure postulated to be related, at least in part, to its mild diuretic effect and the associated reduction in body weight. The consequences of long-term pharmacological inhibition of SGLT-2 are unknown. Individuals with familial renal glucosuria, in whom mutations in the gene coding for SGLT-2 result in substantial glucosuria, are generally healthy. Data from large clinical trials of up to 4 years in duration suggest that dapagliflozin is well tolerated and produces sustained reductions in A1C and body weight. Additional data on the long-term benefits and risks associated with dapagliflozin use are being accumulated through postmarketing surveillance and in the ongoing CV outcomes trial of dapagliflozin (Dapagliflozin Effect on Cardiovascular Events [DECLARE-TIMI 58]), which is assessing the CV safety and potential benefit of dapagliflozin in patients with T2D at high risk for CV events.

In the recently published CV outcomes trial with empagliflozin (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients [EMPA-REG OUTCOME]) in patients with T2D and established CV disease receiving standard of care for other CV risk factors, the primary composite CV outcome of death from CV causes, nonfatal myocardial infarction, or nonfatal stroke occurred in a significantly lower proportion of patients receiving empagliflozin (10.5%) compared with placebo (12.1%; hazard ratio [95% confidence interval], 0.86 [0.74, 0.99]; P=0.04 for superiority). Empagliflozin treatment was also associated with a significantly lower risk of death from any cause (0.68 [0.57, 0.82]; P<0.001), death from CV causes (0.62 [0.49, 0.77]; P<0.001), and hospitalization for heart failure (0.65 [0.50, 0.85]; P=0.002) compared with placebo. There were no significant differences between the empagliflozin and placebo groups in the occurrence of nonfatal myocardial
inclusion (4.5% vs 5.2%; 0.87 [0.70, 1.09]; P=0.22) or nonfatal stroke (3.2% vs 2.6%; 1.24 [0.92, 1.67]; P=0.16). Whether or not these findings are a class effect of SGLT-2 inhibitors remains to be determined. Results of ongoing CV outcome trials with dapagliflozin (DECLARE-TIMI 58)\(^{44}\) and canagliflozin (Canagliflozin Cardiovascular Assessment Study [CANVAS])\(^{45}\) may shed additional light on the potential of SGLT-2 inhibitors to be cardioprotective in patients with T2D.

Dapagliflozin and other SGLT-2 inhibitors are associated with increases in endogenous glucose production and glucagon concentrations that appear to be independent of the reduction in plasma glucose by SGLT-2 inhibition and may partially blunt the glucose-lowering effects of SGLT-2 inhibitors.\(^{47,48}\) SGLT-2 is expressed in pancreatic \(\alpha\)-cells, and inhibition of SGLT-2 with dapagliflozin was shown to increase glucagon secretion from \(\alpha\)-cells in vitro via activation of AMP-sensitive potassium channels, suggesting a potential mechanism for the increase in glucagon.\(^{49}\)

Metformin is a biguanide that has been used for several decades to reduce hyperglycemia in patients with T2D, yet its mechanism of action is still incompletely understood.\(^{50}\) Recently, it has been shown that metformin reduces hepatic glucose production by noncompetitively inhibiting the redox shuttle enzyme mitochondrial glycerophosphate dehydrogenase, thereby altering the hepatocellular redox state,\(^{51}\) which results in activation of AMP-activated protein kinase\(^{52}\) and reduction of hepatic gluconeogenesis.\(^{53}\) Although the main effect of metformin is to suppress hepatic glucose production,\(^{44}\) it may also reduce intestinal absorption of glucose\(^{54}\) and increase peripheral glucose uptake, thereby improving insulin sensitivity.\(^{54}\) Metformin also increases glucagon-like peptide-1 (GLP-1) concentrations\(^{56}\) via a muscarinic 3 receptor and gastrin-releasing peptide receptor–dependent mechanism.\(^{57}\)

The combination of metformin and dapagliflozin targets both insulin-dependent and insulin-independent mechanisms to reduce hyperglycemia. Through both direct and indirect effects, the combination of metformin and dapagliflozin may affect several of the underlying mechanisms that contribute to hyperglycemia (Figure 1), leading to decreased hepatic glucose production (metformin), inhibition of renal reabsorption of glucose (dapagliflozin), improved peripheral insulin sensitivity (metformin and dapagliflozin), improved \(\beta\)-cell function via reduced glucotoxicity (metformin and dapagliflozin), reduced intestinal absorption of glucose (metformin), and possibly increased GLP-1 secretion by L-cells in the colon (metformin\(^{58,59}\)).

### Efficacy studies with the combination of dapagliflozin and metformin

#### Add-on of dapagliflozin to metformin

Patients with inadequate glycemic control (baseline \(A_{1C}\) 7.9%–8.2%) on stable metformin doses (\(\geq 1,500\) mg/d) were randomized to placebo or dapagliflozin (5 or 10 mg/d) in addition to background metformin.\(^{60}\) At 24 weeks, the adjusted mean change in \(A_{1C}\) was significantly greater in patients receiving dapagliflozin 5 (–0.70%) or 10 mg/d (–0.84%, both \(P<0.0001\)) than in those receiving placebo (–0.30%; Table 1). Significantly larger reductions in body weight (–3.0 and –2.9 kg, respectively, \(P<0.0001\)) were observed with both doses of dapagliflozin vs placebo (–0.9 kg). More patients achieved \(A_{1C}\) \(<7%\) with dapagliflozin 5 (37.5%, \(P=0.0275\)) or 10 mg/d (40.6%, \(P=0.0062\)) than with placebo (25.9%). Systolic and diastolic blood pressure, measured as safety variables, decreased by 4–5 and 2–3 mmHg, respectively, with dapagliflozin, compared with decreases of 0.2 and 0.1 mmHg with placebo. The reductions in \(A_{1C}\) and body weight were sustained over 102 weeks of treatment\(^{41}\) (Table 1).

#### Effects of dapagliflozin add-on to metformin on body weight and composition

A randomized, double-blind, placebo-controlled study was conducted to assess changes in body weight and composition by dual-energy X-ray absorptiometry in patients with T2D (baseline \(A_{1C}\) 7.2%, body mass index, 32 kg/m\(^2\)) receiving placebo or dapagliflozin (10 mg/d) add-on to metformin (\(\geq 1,500\) mg/d).\(^{51}\) After 24 weeks, dapagliflozin produced a significantly greater reduction in body weight than placebo (2.96 vs 0.88 kg, \(P<0.0001\); Table 1). A reduction in fat mass accounted for two-thirds of the total weight reduction with dapagliflozin. Although not a primary end point in this trial, dapagliflozin also significantly reduced \(A_{1C}\) compared with placebo (–0.39% vs –0.10%, \(P<0.0001\)). Changes in seated systolic and diastolic blood pressure were –2.7 and –0.7 mmHg with dapagliflozin, respectively, and 0.1 and 0.3 mmHg with placebo. The decreases in body weight, fat mass, and \(A_{1C}\) were maintained over 102 weeks of treatment.\(^{42}\)

#### Add-on of dapagliflozin to insulin ± metformin

Management of patients with inadequate glycemic control on insulin is challenging because increasing insulin
Table 1 Efficacy results of randomized clinical trials with dapagliflozin add-on to metformin

<table>
<thead>
<tr>
<th>Duration, wk</th>
<th>Mean change in A1C%</th>
<th>Mean change in body weight, kg</th>
<th>Percentage of patients with A1C &lt; 7%</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PBO</td>
<td>DAPA, mg/d</td>
<td>PBO</td>
</tr>
<tr>
<td>Add-on to MET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>−0.30</td>
<td>−0.70</td>
<td>−0.84</td>
</tr>
<tr>
<td>102</td>
<td>0.02</td>
<td>−0.58</td>
<td>−0.78</td>
</tr>
<tr>
<td>Add-on to MET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>−0.10</td>
<td>−0.25</td>
<td>−0.39</td>
</tr>
<tr>
<td>102</td>
<td>0.12</td>
<td>−0.30</td>
<td>0.02</td>
</tr>
<tr>
<td>DXA study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>−0.39</td>
<td>−0.89</td>
<td>−0.96</td>
</tr>
<tr>
<td>104</td>
<td>−0.43</td>
<td>−0.82</td>
<td>−0.78</td>
</tr>
<tr>
<td>Add-on to INS</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>−1.35</td>
<td>−2.05</td>
<td>−2.01</td>
</tr>
<tr>
<td>Add-on to MET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>−1.44</td>
<td>−1.98</td>
<td>−2.15</td>
</tr>
</tbody>
</table>

**Notes:** Data are mean changes from baseline. Patients receiving dapagliflozin 5 mg/d were uptitrated to 10 mg/d after 48 weeks of treatment and received this dose for the remainder of the 104-week trial.

**Abbreviations:** A1C, glycated hemoglobin; DAPA, dapagliflozin; DXA, dual-energy X-ray absorptiometry; GLIP, glipizide; INS, insulin; MET, metformin; PBO, placebo; SAXA, saxagliptin.

dose carries the risks of additional weight gain and hypoglycemia. Treatment guidelines suggest considering the addition of other agents, including SGLT-2 inhibitors, to insulin in order to improve glycemic control and reduce the need for additional insulin. In a randomized, placebo-controlled trial, patients with baseline A1C of 8.5%–8.6% and a 13- to 14-year history of T2D received placebo or dapagliflozin (5 or 10 mg/d) in addition to insulin (mean daily dose 77 U) for 24 weeks, followed by extensions up to 104 weeks. Approximately 50% of patients received up to two other oral antidiabetes medications in addition to insulin, primarily metformin (45%–48% of patients). After 24 weeks, dapagliflozin add-on to insulin ± metformin produced larger reductions in A1C (5 mg/d, −0.89%; 10 mg/d, −0.95%) compared with patients receiving placebo (−0.27%). Changes in body weight with dapagliflozin (5 mg/d, −1.58 kg; 10 mg/d, −1.85 kg) were also greater than with placebo (−0.05 kg). Similar to the results from the entire study population, the mean change from baseline to 24 weeks in insulin dose was 6.19 U in the placebo group compared with −0.74 and −1.88 U in the dapagliflozin 5 and 10 mg groups, respectively; the favorable changes in A1C, body weight, and insulin requirements with dapagliflozin were maintained when assessed at 48 and 104 weeks.

In the subgroup of patients treated with both insulin and metformin, the addition of dapagliflozin produced numerically larger reductions in A1C (5 mg/d, −0.89%; 10 mg/d, −0.95%) compared with patients receiving placebo (−0.27%). Changes in body weight with dapagliflozin (5 mg/d, −1.58 kg; 10 mg/d, −1.85 kg) were also greater than with placebo (−0.05 kg). Similar to the results from the entire study population, the mean change from baseline to 24 weeks in insulin dose was 6.19 U in the placebo group compared with −0.74 and −1.88 U in the dapagliflozin 5 and 10 mg groups, respectively; the favorable changes in A1C, body weight, and insulin requirements with dapagliflozin were maintained when assessed at 48 and 104 weeks.

Dapagliflozin add-on vs glipizide add-on to metformin

The efficacy and safety of dapagliflozin compared with glipizide as add-on to metformin was assessed in a 52-week...
noninferiority trial in patients with T2D inadequately controlled with metformin. Patients with baseline $A_{IC}$ of 7.7% on stable metformin doses (1,500–2,500 mg/d) received double-blind dapagliflozin uptitrated from 2.5 mg/d to a maximum of 10 mg/d or glipizide 5 mg/d uptitrated to a maximum of 20 mg/d if fasting plasma glucose was $\geq 6.1$ mmol/L during an 18-week titration period. At the end of the titration period, the mean doses of dapagliflozin and glipizide were 9.2 and 16.4 mg/d, respectively. After 52 weeks of treatment, the adjusted mean change from baseline in $A_{IC}$ was $-0.52\%$ in the two groups, meeting the study’s primary end point of noninferiority. Dapagliflozin produced body weight reduction (−3.2 kg; $P<0.0001$), whereas glipizide led to an increase in weight (1.4 kg; Table 1). Mean changes from baseline in systolic and diastolic blood pressure with dapagliflozin were −4.3 and −1.6 mmHg vs 0.8 and −0.4 mmHg with glipizide, respectively. $A_{IC}$ reduction and decreases in body weight appeared more sustained with dapagliflozin than glipizide over 208 weeks of treatment (Table 1), and reductions in blood pressure with dapagliflozin were sustained with continued treatment.$^{40,64}$

**Initial combination of dapagliflozin with metformin in treatment-naïve patients**

For patients presenting with $A_{IC} \geq 9\%$, treatment guidelines recommend combination therapy to achieve individualized glycemic targets.$^{30,31}$ Two studies assessed the effects of initial combination of dapagliflozin (one study with a dose of 5 mg/d and the other study with a dose of 10 mg/d) and metformin extended release (median dose 2,000 mg/d) compared with dapagliflozin plus placebo and metformin plus placebo in treatment-naïve patients with baseline $A_{IC}$ 9.1%–9.2%. In the study with the 5 mg/d dose, after 24 weeks of treatment, mean reductions from baseline in $A_{IC}$ were −2.05% for dapagliflozin plus metformin ($P<0.0001$ vs metformin plus placebo), −1.35% for metformin plus placebo, and −1.19% for dapagliflozin plus placebo. In the study with the 10 mg/d dose, mean reductions from baseline to 24 weeks in $A_{IC}$ were −1.98%, −1.44%, and −1.45% for dapagliflozin plus metformin ($P<0.0001$ vs metformin plus placebo), metformin plus placebo, and dapagliflozin plus placebo, respectively (Table 1). In a prespecified analysis, the change in $A_{IC}$ with dapagliflozin 10 mg/d plus placebo was noninferior to the change with metformin plus placebo. In both studies, weight reduction was greater with dapagliflozin vs placebo, and a larger proportion of patients achieved $A_{IC} < 7\%$ with dapagliflozin than with placebo (Table 1).

**Dual add-on of saxagliptin plus dapagliflozin to metformin**

As glycemic control worsens, patients typically receive stepwise therapy with sequential addition of single oral agents to metformin. A clinical trial evaluated dual add-on of combination treatment consisting of the dipeptidyl peptidase-4 inhibitor saxagliptin (5 mg/d) and dapagliflozin (10 mg/d) to metformin (≥1,500 mg/d) as triple therapy compared with the addition of each of the individual components singly to metformin as dual therapy.$^{46}$ Patients had a mean baseline $A_{IC}$ of 8.94% and T2D duration of 7.6 years. The addition of saxagliptin plus dapagliflozin to metformin therapy resulted in significantly greater adjusted mean reductions from baseline in $A_{IC}$ at 24 weeks than did therapy with saxagliptin add-on to metformin ($P<0.0001$) or dapagliflozin add-on to metformin ($P=0.0166$; Table 1). The reduction in body weight was greatest in the dapagliflozin-containing treatment arms, and the proportion of patients achieving $A_{IC} < 7\%$ at week 24 with the dual add-on, although not tested for statistical significance, was almost double that seen in the single add-on groups.

In these clinical trials, dapagliflozin produced significant and sustained reductions in $A_{IC}$ and body weight when given in combination with metformin. Although not shown, dapagliflozin also significantly reduced fasting plasma glucose$^{37,60,61,65,66}$ and, when measured, postprandial glucose.$^{56}$ These changes were accompanied by modest decreases in blood pressure. In an analysis of data pooled from 13 placebo-controlled trials, dapagliflozin reduced blood pressure in both normotensive and hypertensive patients with T2D, without changes in heart rate.$^{57}$ The changes in blood pressure may be partly the result of mild osmotic diuresis$^{38}$ and weight loss.$^{48}$ Thus, dapagliflozin add-on to metformin improves glycemic control and has favorable effects on CV risk factors.

**Safety and tolerability of dapagliflozin and metformin combination therapy**

In clinical trials with dapagliflozin, the most common (≥5%) adverse events (AEs) included nasopharyngitis, headache, upper respiratory infection, diarrhea, and back pain. In addition, certain AEs were considered to be of special interest based on the mechanism of action of dapagliflozin. These included signs, symptoms, or other reports suggestive of genital and urinary tract infections, renal AEs (renal failure or impairment), diuresis/volume-related
AEs (hypotension, hypovolemia, and dehydration), and hypoglycemia.\textsuperscript{37,60,61,63,65,66} Occurrence of these AEs in clinical trials of 24- to 52-week duration will now be discussed. For trials with long-term extension periods, with total duration of up to 102–208 weeks, a similar pattern of AEs was observed.\textsuperscript{40–43,64}

Add-on of dapagliflozin to metformin

The proportion of patients with ≥1 AE was similar in the dapagliflozin (69%–73%) and placebo (64%) groups.\textsuperscript{60} The incidence of urinary tract infections with dapagliflozin (7%–8%) was similar to placebo (8%), but genital infections were more frequent in the dapagliflozin groups (9%–13%) compared with placebo (5%). Diuresis-related AEs were uncommon (≤1%) across all treatment groups, as were events of hypoglycemia (dapagliflozin, 4%; placebo, 3%).

Effects of dapagliflozin add-on to metformin on body weight and composition

Similar proportions of patients had ≥1 AE with dapagliflozin (43%) and placebo (40%). Genital (3% vs 0%) and urinary tract infections (7% vs 2%) were more common with dapagliflozin than with placebo.\textsuperscript{37} Hypoglycemia events were similar in the dapagliflozin (2%) and placebo (3%) groups.

Add-on of dapagliflozin to insulin ± metformin

The percentage of patients experiencing ≥1 AE was similar across treatment groups (72%–74%).\textsuperscript{61} Patients receiving dapagliflozin, compared with those receiving placebo, had more genital infections (10%–11% vs 3%) and urinary tract infections (10%–11% vs 5%). Renal AEs (2%–3% vs 2%) and volume-related AEs (2% vs 1%) were infrequent and similar between the dapagliflozin and placebo groups. As expected with insulin therapy, sizable but similar proportions of patients had ≥1 episode of hypoglycemia with dapagliflozin (54%–56%) and placebo (52%). Major episodes of hypoglycemia (defined as a symptomatic episode in which the patient required external assistance because of severe impairment in consciousness or behavior, had a capillary or plasma glucose level <54 mg/dL, and promptly recovered after receiving glucose or glucagon) occurred in 1%–2% of patients in the dapagliflozin groups and 1% of patients in the placebo group.

In the subgroup of patients on background metformin, the proportion of patients with ≥1 AE was higher with dapagliflozin (68%) than with placebo (59%) during the 104-week extended treatment period.\textsuperscript{62} Urinary tract and genital infections were more frequent with dapagliflozin (11%–18% and 12%–15%, respectively) than with placebo (3% and 5%, respectively). Renal and volume-related AEs were infrequent (2%–3%) and similar between dapagliflozin and placebo groups. A greater proportion of patients experienced hypoglycemia with dapagliflozin (54%–60%) than with placebo (39%). There was one event (1%) of major hypoglycemia with dapagliflozin and none with placebo.

Dapagliflozin add-on vs glipizide add-on to metformin

The proportion of patients with ≥1 AE was 78% with both dapagliflozin and glipizide.\textsuperscript{63} Genital and urinary tract infections were more common with dapagliflozin (12% and 11%, respectively) than with glipizide (3% and 6%, respectively). Renal AEs with dapagliflozin (6%) were more frequent than with glipizide (3%). Volume-related AEs were infrequent (dapagliflozin, 2%; glipizide, 1%). Events of hypoglycemia were ≥10-fold lower with dapagliflozin (3%) compared with glipizide (40%). Three patients (0.7%) in the glipizide group had a major episode of hypoglycemia compared with none in the dapagliflozin group.

Initial combination of dapagliflozin with metformin in treatment-naïve patients

Similar proportions of patients had ≥1 AE with dapagliflozin 5 and 10 mg/d plus metformin (69% and 60%, respectively) compared with dapagliflozin plus placebo (53% and 60%) and metformin plus placebo (59% and 57%).\textsuperscript{64} Genital infections were more common with dapagliflozin 5 (7%) and 10 mg/d (9%) plus metformin and dapagliflozin plus placebo (7% and 13%) compared with metformin plus placebo (2%). The incidence of urinary tract infections was 8% for dapagliflozin 5 mg/d plus metformin, metformin plus placebo, and dapagliflozin 5 mg/d plus placebo but was higher with dapagliflozin 10 mg/d plus metformin (8%) and dapagliflozin 10 mg/d plus placebo (11%) than with metformin plus placebo (4%). Volume-related AEs were infrequent with dapagliflozin plus metformin (≤0.5%) and dapagliflozin plus placebo (≤2%), and no events were reported with metformin plus placebo. Hypoglycemia occurrence was similar with dapagliflozin plus metformin (3%), dapagliflozin plus placebo (0%–1%), and metformin plus placebo (0%–3%), and no episodes of major hypoglycemia were reported in either study.
Dual add-on of saxagliptin plus dapagliflozin to metformin

The proportion of patients experiencing ≥1 AE was similar across treatment groups (49%–53%). Genital infections were more common in the dapagliflozin plus metformin group (6%) compared with the saxagliptin and dapagliflozin plus metformin group (0) and the saxagliptin plus metformin group (<1%). Urinary tract infections were more common in the saxagliptin plus metformin (5%) and dapagliflozin plus metformin groups (4%) than in the saxagliptin and dapagliflozin plus metformin group (0.6%). Events of hypoglycemia were few and occurred in similar proportions across the three treatment groups (1%), and no episodes of major hypoglycemia were reported.

Overall summary of safety

Overall, dapagliflozin as add-on therapy to metformin was well tolerated and associated with low rates of hypoglycemia. Genital infections and, in some studies, urinary tract infections were more frequent with dapagliflozin than with placebo. This appears to be a class effect of the SGLT-2 inhibitors. The increase in genital infections in patients with T2D receiving dapagliflozin may be related to glucosuria, but a relationship between urinary tract infections and glucosuria in the context of SGLT-2 inhibition is less clear. In the dapagliflozin clinical development program, both genital and urinary tract infections were generally mild to moderate, rarely led to discontinuation, and were typically managed with standard antimicrobial or antifungal agents. According to spontaneous reports to the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), 19 patients receiving SGLT-2 inhibitors experienced urosepsis or pyelonephritis from March 2013 through October 2014. All patients were hospitalized, and a few were admitted to an intensive care unit or underwent dialysis for the treatment of kidney failure. However, we note that FAERS provides no data on the denominator or the incidence of pyelonephritis in patients with T2D not taking SGLT-2 inhibitors. Dapagliflozin has a mild diuretic effect, but volume-related AEs were uncommon in clinical trials. Because the mechanism of action of SGLT-2 inhibitors depends on glomerular filtration rate (GFR) and because of concerns of increased AE frequency in patients with moderate renal impairment, dapagliflozin should not be used in patients with an estimated GFR <60 mL/min/1.73 m².

The FDA recently issued a drug safety communication that warned of an increased risk of diabetic ketoacidosis (DKA) associated with SGLT-2 inhibitor use. Between March 2013 and May 2015, 73 cases of DKA were identified in patients (mostly with T2D) treated with SGLT-2 inhibitors. In the dapagliflozin clinical development program of more than 18,000 patients treated with dapagliflozin, reports of events suggestive of DKA were rare (<0.1%). DKA is usually associated with marked hyperglycemia (>250 mg/dL) as the result of insulin deficiency. DKA associated with SGLT-2 inhibitor use may present with smaller or even no increases in plasma glucose concentrations (“euglycemic DKA”) likely related to increased urinary glucose excretion. In addition, it has been shown that SGLT-2 inhibitors increase plasma glucagon concentrations. It is postulated that lipolysis and ketogenesis are stimulated as a result of a lower insulin:glucagon ratio and reduced glucose availability. An assessment of DKA risk in both T1D and T2D has recently been conducted by the American Association of Clinical Endocrinologists, a summary of which is available online. Patients and health care providers need to be aware of the signs and symptoms of DKA and the measures used to recognize and treat it.

Patient-focused perspectives: quality of life, satisfaction, and acceptability

Patient preference and quality of life (QoL) are important considerations when choosing pharmacotherapy in T2D, especially in view of the relatively low patient adherence to antidiabetes medications that can lead to increased hospitalization and mortality. Health-related QoL was evaluated in patients participating in a dapagliflozin add-on to metformin trial. Perceived health status and QoL were evaluated with the EuroQol-5 (EQ-5D), a standardized index of health status that consists of measures of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Overall, patient-reported QoL was high at weeks 24, 50, and 102, and there were no statistical differences in EQ-5D scores at any time point between dapagliflozin and placebo groups. Thus, high health-related QoL scores were maintained from baseline to 102 weeks with dapagliflozin add-on to metformin.

Weight loss-related QoL was also analyzed using the Study to Help Improve Early Evaluation and Management of Risk Factors Leading to Diabetes Weight Questionnaire-9 (SHIELD-WQ-9), a weight change-related QoL survey. At week 24, significantly more patients in the dapagliflozin group reported improvements in overall health-related QoL (29.3%, P=0.02) than those in the placebo group (14.0%). QoL scores were numerically higher with dapagliflozin...
Clinical practice experience
Dapagliflozin reduces blood glucose concentrations, body weight, and systolic blood pressure when combined with metformin. Although dapagliflozin is generally well tolerated, there are some practical recommendations to reduce potential side effects. For example, because of the modest diuretic effect of dapagliflozin, volume status should be checked, especially in the elderly, and doses of diuretics and other antihypertensive medications should be adjusted to avoid the potential for hypovolemia. Patients should be encouraged to increase fluid intake and to expect an increase in urination and possibly nocturia. Renal function should be assessed before initiating dapagliflozin treatment and monitored during therapy.

Patients should be advised of the increased risk of genital and urinary tract infections associated with SGLT-2 inhibitors, especially in patients with a history of such infections. Patients need to be counseled that the risk of infection can be minimized by increasing fluid intake and by fastidious bathroom habits and preventative measures such as the routine use of hygienic wipes or sprays.

Conclusion and the place of dapagliflozin add-on to metformin in therapy
Guidelines generally recommend sequential treatment of T2D with addition of agents if treatment goals are not achieved after a specified period, typically 3 months. By using serum fructosamine concentrations, which reflect average glycemic control over 1 month, therapeutic decisions can be made even faster. Because of the risks of hypoglycemia and concerns coming from the ADVANCE, ACCORD, and VADT data, guidelines also suggest less stringent glycemic targets for some patients, including older patients, those with longer disease duration, shorter life expectancy, significant comorbidities, established vascular complications, limited support systems, or diminished capacity for self-care.

However, given the known consequences of chronic hyperglycemia and our emerging understanding of the pathophysiology of T2D, early combination therapy with agents with complementary mechanisms of action that are not associated with weight gain and do not increase the risk of hypoglycemia may be appropriate therapy to enable patients, including the elderly and those with longer disease duration, short life expectancy, significant comorbidities, or established vascular complications, to achieve individualized glycemic goals.

The combination of dapagliflozin and metformin provided sustained glycemic control and reductions in body weight for up to 208 weeks, without increased risk of hypoglycemia, both as initial combination therapy in treatment-naïve patients and in patients with inadequate response to metformin monotherapy. The combination of dapagliflozin and metformin is an attractive alternative to a sulfonylurea or thiazolidinedione plus metformin, especially in patients at risk of hypoglycemia or in patients who want to avoid weight gain.

Acknowledgments
Medical writing support for the preparation of this manuscript was provided by Richard Edwards, PhD, and Janet Matsuura, PhD, from Complete Healthcare Communications, LLC (Chadds Ford, PA), with funding from AstraZeneca.

Disclosure
SS has served as an advisory board member for Janssen, Merck, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Salix, Novo Nordisk, Takeda, and Genesis Biotechnology Group and on the speakers bureaus of Takeda, Janssen, Merck, Novo Nordisk, Salix, Boehringer Ingelheim, Eli Lilly, Eisai, AstraZeneca, GlaxoSmithKline, and Amgen. AK was an employee of AstraZeneca during the development of this manuscript. The authors report no other conflicts of interest in this work.

References


55. Glucophage® (Metformin HCl tablets) and Glucophage XR® (Metformin HCl) extended-release tablets [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; 2009.


73. Farxiga® (Dapagliflozin) [prescribing information]. Wilmington, DE: AstraZeneca; 2015.


